Effects of Low/No Calorie Sweeteners on Glucose Tolerance

Status Completed

Clinical Trial Summary

This study aims to determine the effects of chronic exposure to some low/no calorie sweeteners (LNCS) on glucose tolerance and glucagon like peptide 1 (GLP-1) release in healthy individuals. LNCS examined in this study are saccharin, sucralose and aspartame+acesulfame-K. The amounts of LNCS given to the participants are kept similar to daily life exposure; far less than the Acceptable Daily Intakes (ADIs) levels proposed by Food and Drug Administration (FDA) or European Food Safety Authority (EFSA).

Clinical Trial Description

Excessive sugar consumption has been related to chronic metabolic problems, including obesity, type 2 diabetes, neuroinflammatory diseases, etc. Therefore, it is recommended to decrease added sugar intake below 10% of total energy intake. Low/no calorie sweeteners (LNCS) may seem as a good alternative to added sugars because they provide sweetness without adding calories to the diet. Although they may reduce energy intake and prevent weight gain, studies investigating the short and long term effects of these sweeteners on metabolic profile are controversial. Therefore, there is a need for future studies to shed light on metabolic effects of these compounds in humans. Some observational and clinical studies show that they may cause insulin resistance and type 2 diabetes. There are possible mechanisms that may explain this relationship. One of these possible mechanisms is interaction with sweet taste receptors (STRs). It has been shown that STRs not only found in oral cavity but also in extra-oral tissues, such as gastrointestinal tract, pancreas, brain, etc. In vitro studies with sucralose, it has been shown that it may activate STRs in L-cells and stimulate GLP-1 release in a similar manner with glucose. However, these results were not confirmed in vivo. There are at least six different LNCS approved for human use worldwide. However, each of them have different biological fate in terms of absorption, metabolism and excretion characteristics in the body. Therefore, result of a study with one of LNCS cannot be extrapolated for all LNCS; each of them should be studied in well-designed studies. In this study it is hypothesized that LNCS may activate STRs in intestinal L-cells and alter release of GLP-1; as a result impair glucose tolerance. In acute human studies, these effects are tested and there are controversial results in regard to glucose tolerance or incretin release. However, individuals who want to consume fewer calories or to better control their blood glucose use LNCS in place of sugar for longer period of time. For this reason, we wanted to test the effects of regular use of LNCS on glucose tolerance and incretin release. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04904133
Study type	Interventional
Source	Acibadem University
Contact
Status	Completed
Phase	N/A
Start date	April 2, 2019
Completion date	July 2, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05534477` - Verily Clinical Study Watch Analytical Validation Study
Active, not recruiting	`NCT06314659` - Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months	Phase 3
Not yet recruiting	`NCT05827198` - Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in Candies	N/A
Completed	`NCT05794100` - Evaluating the Impact of Different Sugar Replacer Combinations on Gastrointestinal Tolerance	N/A
Completed	`NCT03797599` - Study Examining the Effects of Mindfulness and Similar Audio-guided Exercises.	N/A
Recruiting	`NCT05323032` - Multifocal Electroretinogram in Normal Egyptian Population	N/A
Completed	`NCT03509818` - Effects of the Physical Fitness on Serum Klotho Levels in Healthy Population	N/A
Active, not recruiting	`NCT05339841` - Italian Digital Primary Cardiovascular Prevention Study	N/A
Completed	`NCT05193799` - Evaluation of the Tolerance of Three Masks Under Dermatological Control.	N/A
Completed	`NCT03067532` - Assessment of Educational Effect of Home-made Robotic Surgery Simulator for Novice Robotic Surgeons	N/A
Completed	`NCT04582994` - The Role of Beta Oscillation in Mental Time Travel
Active, not recruiting	`NCT05999916` - Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants	N/A
Active, not recruiting	`NCT06314685` - Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years	Phase 3
Not yet recruiting	`NCT05996042` - Time-restricted Diet Combined With Multimodal Aerobic Exercise	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.